Literature DB >> 21414238

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.

Zaid Al-Hamodi1, Ikram S Ismail, Riyadh Saif-Ali, Khaled A Ahmed, Sekaran Muniandy.   

Abstract

BACKGROUND: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1 and tPA activities and antigens in Malaysian T2D and normal subjects.
METHODS: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 non-diabetic MetS subjects.
RESULTS: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 × 10⁻¹⁹) and non-diabetic subjects with MetS (P = 3.0 × 10⁻¹⁵), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 × 10⁻²⁴), T2D without MetS (P = 1.3 × 10⁻¹³) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects were related to insulin resistance (P = 2.2 × 10⁻⁴; 0.007). Additionally, the PAI-1 activity was associated with an increased waist circumference (P = 2.2 × 10⁻⁴) and decreased HDL-c (P = 0.005), whereas the tPA activity was associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen (R² = 0.695, P = 1.1 × 10⁻³⁶) in diabetic subjects. The tPA activity negatively correlated with its antigen (R² = -0.444, P = 7.7 × 10⁻¹³) in normal subjects and with the PAI-1 activity and antigen (R² = -0.319, P = 9.9 × 10⁻¹²; R² = -0.228, P = 3.4 × 10⁻⁶) in diabetic subjects.
CONCLUSIONS: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in Malaysian subjects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414238      PMCID: PMC3064636          DOI: 10.1186/1475-2840-10-23

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN: 1475-2840            Impact factor:   9.951


  61 in total

Review 1.  The adipocyte and hemostatic balance in obesity: studies of PAI-1.

Authors:  D J Loskutoff; F Samad
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-01       Impact factor: 8.311

2.  Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma.

Authors:  B Wiman; A Almquist; O Sigurdardottir; T Lindahl
Journal:  FEBS Lett       Date:  1988-12-19       Impact factor: 4.124

Review 3.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study.

Authors:  Y Arad; D Newstein; F Cadet; M Roth; A D Guerci
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

5.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

6.  New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents.

Authors:  Barbara Glowinska; Miroslawa Urban; Alicja Koput; Marzena Galar
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

7.  Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

Authors:  Li-Jun Ma; Su-Li Mao; Kevin L Taylor; Talerngsak Kanjanabuch; YouFei Guan; YaHua Zhang; Nancy J Brown; Larry L Swift; Owen P McGuinness; David H Wasserman; Douglas E Vaughan; Agnes B Fogo
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

8.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

9.  Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease.

Authors:  P Båvenholm; A Proudler; A Silveira; D Crook; M Blombäck; U de Faire; A Hamsten
Journal:  Thromb Haemost       Date:  1995-04       Impact factor: 5.249

10.  Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men.

Authors:  Johan Arnlöv; Erik Ingelsson; Johan Sundström; Lars Lind
Journal:  Circulation       Date:  2009-12-28       Impact factor: 29.690

View more
  17 in total

1.  Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?

Authors:  Olga V Saik; Vadim V Klimontov
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Association of polymorphisms in mitofusin-2 gene with type 2 diabetes in Han Chinese.

Authors:  Pengtao Li; Shuying Zhu; Xiaopan Wu; Xilin Zhu; Jingyun Li; Liping Pan; Zhenhui Xin; Fenghe Niu; Jia Wu; Ying Liu
Journal:  J Biomed Biotechnol       Date:  2012-06-18

3.  Study of the correlations among some parameters of the oxidative status, gelatinases, and their inhibitors in a group of subjects with metabolic syndrome.

Authors:  E Hopps; R Lo Presti; M Montana; B Canino; M R Averna; G Caimi
Journal:  Mediators Inflamm       Date:  2014-07-10       Impact factor: 4.711

4.  Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease.

Authors:  Elsa Aburto-Mejía; David Santiago-Germán; Manuel Martínez-Marino; Eduardo Almeida-Gutiérrez; Mardia López-Alarcón; Jesús Hernández-Juárez; Antonio Alvarado-Moreno; Alfredo Leaños-Miranda; Abraham Majluf-Cruz; Irma Isordia-Salas
Journal:  Biomed Res Int       Date:  2017-02-08       Impact factor: 3.411

5.  Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.

Authors:  Masaya Sakamoto; Hirofumi Suzuki; Takeshi Hayashi; Hiroyuki Iuchi; Tsuyoshi Isaka; Noriko Sakamoto; Yosuke Kayama; Katsuyoshi Tojo; Michihiro Yoshimura; Kazunori Utsunomiya
Journal:  Cardiovasc Diabetol       Date:  2012-10-03       Impact factor: 9.951

6.  Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.

Authors:  Zaid Al-Hamodi; Riyadh Saif-Ali; Ikram S Ismail; Khaled A Ahmed; Sekaran Muniandy
Journal:  J Biomed Biotechnol       Date:  2012-04-11

7.  Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.

Authors:  Jenny Hernestål-Boman; Margareta Norberg; Jan-Hakan Jansson; Mats Eliasson; Jan W Eriksson; Bernt Lindahl; Lars Johansson
Journal:  Cardiovasc Diabetol       Date:  2012-12-18       Impact factor: 9.951

8.  Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects.

Authors:  Zaid H Al-Hamodi; Riyadh Saif-Ali; Ikram S Ismail; Khaled A Ahmed; Sekaran Muniandy
Journal:  J Clin Biochem Nutr       Date:  2011-11-11       Impact factor: 3.114

Review 9.  Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.

Authors:  James Yarmolinsky; Natália Bordin Barbieri; Tobias Weinmann; Patricia K Ziegelmann; Bruce B Duncan; Maria Inês Schmidt
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

10.  A proteomic signature that reflects pancreatic beta-cell function.

Authors:  Aoife M Curran; Marie Pier Scott-Boyer; Jim Kaput; Miriam F Ryan; Elaine Drummond; Eileen R Gibney; Michael J Gibney; Helen M Roche; Lorraine Brennan
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.